Community Guidelines

Twitter Community Guidelines

AveXis, Inc. is open to the opportunity to engage with individuals and organizations via Twitter. As a clinical stage gene therapy company, we are dedicated to developing and commercializing novel treatments for patients suffering from rare and life-threatening neurological genetic diseases. However, there are strict regulatory and legal procedures we must follow when communicating via social media.

According to the AveXis community guidelines, the following content may not be replied to and/or may be deleted from the AveXis corporate Twitter feed:

  1. Violations of copyright or intellectual property of others
  2. Mentions of misleading or deceptive content
  3. Content that includes product or treatment options
  4. Violations of Twitter’s Platform Rules
  5. Content that provides health or medical advice
  6. Spam or messages not related to AveXis or its core focus
  7. Content intended to recruit followers
  8. Content that includes offensive or derogatory remarks

Since our current AveXis Twitter handle is intended for U.S. audiences only, AveXis will only respond to tweets in English.

Twitter accounts that AveXis follows, are followed by, or content that third-party Twitter handles retweet or favorite are not an indication of an AveXis endorsement of these accounts or the content they produce.

Adverse Events or Medical Side Effects

At this time, AveXis does not have a product approved for commercial use. If you believe that you have experienced any medical or adverse side effects related to an AveXis investigational product, please consult 844.428.3947 immediately. You can also report these to us directly by emailing medinfo@avexis.com.

Using and Storing Personal Information

We do not aim to store or use your Twitter profile unique ID, email or other personal details. Please view the AveXis Privacy Policy. However, in case of an adverse event or product issue you report, we would need to store and use information about you, such as your name, location, health-related information. This information is required to be submitted to the AveXis drug safety department (medinfo@avexis.com) and/or regulatory authorities.

Please note that Twitter has its own policies. For more information, please view the Twitter Privacy Policy.

We appreciate your understanding and your interest in following @AveXisInc on Twitter.